GILEAD SCIENCES INC (NASDAQ: GILD)

GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Last update: 25 Nov, 6:10PM

90.49

0.30 (0.33%)

Add to watchlist

Previous Close	90.19
Open	90.93
Volume	10,641,237
Avg. Volume (3M)	6,668,701
Market Cap	112,774,963,200

Price / Earnings (TTM)	1,005.44
Price / Earnings (Forward)	12.22
Price / Sales	4.06
Price / Book	6.21

52 Weeks Range	62.07 (-31%) — 98.90 (9%)
Earnings Date	4 Feb 2025 - 10 Feb 2025
TTM Dividend Yield	3.40%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bullish	Bullish
	Drug Manufacturers - General (Global)	Bullish	Bullish
Stock	Gilead Sciences, Inc.	Bullish	Bullish

AIStockmoo Score

-0.9

Analyst Consensus	1.5
Insider Activity	-2.5
Price Volatility	-0.5
Technical Moving Averages	-2.5
Technical Oscillators	-0.5
Average	-0.90

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
GILD	113 B	3.40%	1,005.44	6.21
AMGN	143 B	3.38%	34.01	19.33
AZN	240 B	1.93%	37.45	5.19
SNY	120 B	8.54%	25.24	1.55
GRFS	6 B	-	32.20	0.830
BIIB	23 B	-	14.35	1.31

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector	Healthcare
Industry	Drug Manufacturers - General
Investment Style	Large Value
% Held by Insiders	0.12%
% Held by Institutions	88.40%

52 Weeks Range	62.07 (-31%) — 98.90 (9%)
Price Target Range	80.00 (-11%) — 125.00 (38%)
High	125.00 (Citigroup, 38.14%)	Buy
Median	101.00 (11.62%)
Low	80.00 (Cantor Fitzgerald, -11.59%)	Hold
Average	100.44 (11.00%)
Total	11 Buy, 7 Hold
Avg. Price @ Call	93.61

Firm	Date	Target Price	Call	Price @ Call
Cantor Fitzgerald	11 Dec 2024	80.00 (-11.59%)	Hold	92.38
Cantor Fitzgerald	07 Nov 2024	80.00 (-11.59%)	Hold	97.90
RBC Capital	11 Dec 2024	84.00 (-7.17%)	Hold	92.38
RBC Capital	18 Nov 2024	84.00 (-7.17%)	Hold	88.46
B of A Securities	10 Dec 2024	109.00 (20.46%)	Buy	92.34
Oppenheimer	10 Dec 2024	115.00 (27.09%)	Buy	92.34
Oppenheimer	07 Nov 2024	105.00 (16.03%)	Buy	97.90
Mizuho	21 Nov 2024	100.00 (10.51%)	Buy	89.76
UBS	21 Nov 2024	96.00 (6.09%)	Hold	89.76
Wolfe Research	15 Nov 2024	110.00 (21.56%)	Buy	88.40
Citigroup	14 Nov 2024	125.00 (38.14%)	Buy	92.11
Truist Securities	08 Nov 2024	97.00 (7.19%)	Hold	96.57
BMO Capital	07 Nov 2024	102.00 (12.72%)	Buy	97.90
BMO Capital	17 Oct 2024	94.00 (3.88%)	Buy	87.36
Baird	07 Nov 2024	95.00 (4.98%)	Hold	97.90
Barclays	07 Nov 2024	95.00 (4.98%)	Hold	97.90
Barclays	07 Oct 2024	84.00 (-7.17%)	Hold	84.43
Goldman Sachs	07 Nov 2024	84.00 (-7.17%)	Hold	97.90
JP Morgan	07 Nov 2024	105.00 (16.03%)	Buy	97.90
JP Morgan	09 Oct 2024	100.00 (10.51%)	Buy	86.14
Piper Sandler	07 Nov 2024	105.00 (16.03%)	Buy	97.90
Wells Fargo	07 Nov 2024	105.00 (16.03%)	Buy	97.90
Wells Fargo	07 Oct 2024	100.00 (10.51%)	Buy	84.43
Leerink Partners	21 Oct 2024	96.00 (6.09%)	Buy	86.29
Bernstein	17 Oct 2024	105.00 (16.03%)	Buy	87.36
Show more

Name	Avg. Buy ($)	Avg. Sell ($)	Net Quantity	Net Value ($)
DICKINSON ANDREW D	-	92.34	-1,686	-155,685
MERCIER JOHANNA	-	92.34	-1,739	-160,579
O'DAY DANIEL PATRICK	-	92.34	-4,762	-439,723
PARSEY MERDAD	-	92.34	-1,771	-163,534
PATTERSON SANDRA	-	92.10	-565	-52,097
TELMAN DEBORAH H	-	92.34	-306	-28,256
Aggregate Net Quantity				-10,829
Aggregate Net Value ($)				-999,875
Aggregate Avg. Buy ($)				-
Aggregate Avg. Sell ($)				92.27

Name	Holder	Date	Type	Quantity	Price	Value ($)
PATTERSON SANDRA	Officer	13 Dec 2024	Disposed (-)	157	91.86	14,422
PATTERSON SANDRA	Officer	13 Dec 2024	Option execute	157	-	-
DICKINSON ANDREW D	Officer	10 Dec 2024	Disposed (-)	1,686	92.34	155,685
DICKINSON ANDREW D	Officer	10 Dec 2024	Option execute	3,640	-	-
MERCIER JOHANNA	Officer	10 Dec 2024	Disposed (-)	1,739	92.34	160,579
MERCIER JOHANNA	Officer	10 Dec 2024	Option execute	3,752	-	-
O'DAY DANIEL PATRICK	Officer	10 Dec 2024	Disposed (-)	4,762	92.34	439,723
O'DAY DANIEL PATRICK	Officer	10 Dec 2024	Option execute	10,295	-	-
PARSEY MERDAD	Officer	10 Dec 2024	Disposed (-)	1,771	92.34	163,534
PARSEY MERDAD	Officer	10 Dec 2024	Option execute	3,820	-	-
TELMAN DEBORAH H	Officer	10 Dec 2024	Disposed (-)	306	92.34	28,256
TELMAN DEBORAH H	Officer	10 Dec 2024	Option execute	639	-	-
PATTERSON SANDRA	Officer	10 Dec 2024	Disposed (-)	408	92.34	37,675
PATTERSON SANDRA	Officer	10 Dec 2024	Option execute	901	-	-
Show more

Date	Type	Details
17 Dec 2024	Announcement	U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
17 Dec 2024	Announcement	Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
13 Dec 2024	Announcement	Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
12 Dec 2024	Announcement	Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
09 Dec 2024	Announcement	Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
09 Dec 2024	Announcement	Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
08 Dec 2024	Announcement	Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
03 Dec 2024	Announcement	Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
27 Nov 2024	Announcement	Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
15 Nov 2024	Announcement	Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
13 Nov 2024	Announcement	Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
13 Nov 2024	Announcement	Gilead Prices $3.5 Billion of Senior Unsecured Notes
12 Nov 2024	Announcement	Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
08 Nov 2024	Announcement	Gilead Sciences to Present at Upcoming Investor Engagements
07 Nov 2024	Announcement	Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
06 Nov 2024	Announcement	Gilead Sciences Announces Third Quarter 2024 Financial Results
05 Nov 2024	Announcement	Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
31 Oct 2024	Announcement	AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
22 Oct 2024	Announcement	Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
19 Oct 2024	Announcement	Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
09 Oct 2024	Announcement	Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
09 Oct 2024	Announcement	Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
07 Oct 2024	Announcement	Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
02 Oct 2024	Announcement	Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
02 Oct 2024	Announcement	Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
Show more

TTM Dividend Yield	3.40%
5Y Average Dividend Yield	3.91%
Payout Ratio	3,400.00%
Expected Next Dividend Payment	Mar 2025

Ex Date	Announcement Date	Payment Date	Details
13 Dec 2024	30 Oct 2024	30 Dec 2024	0.77 Cash
13 Sep 2024	30 Jul 2024	27 Sep 2024	0.77 Cash
14 Jun 2024	23 Apr 2024	27 Jun 2024	0.77 Cash
14 Mar 2024	01 Feb 2024	28 Mar 2024	0.77 Cash
14 Dec 2023	01 Nov 2023	28 Dec 2023	0.75 Cash
14 Sep 2023	25 Jul 2023	28 Sep 2023	0.75 Cash
14 Jun 2023	25 Apr 2023	29 Jun 2023	0.75 Cash
14 Mar 2023	25 Jan 2023	30 Mar 2023	0.75 Cash
14 Dec 2022	25 Oct 2022	29 Dec 2022	0.73 Cash
14 Sep 2022	25 Jul 2022	29 Sep 2022	0.73 Cash
14 Jun 2022	27 Apr 2022	29 Jun 2022	0.73 Cash
14 Mar 2022	28 Jan 2022	30 Mar 2022	0.73 Cash
14 Dec 2021	26 Oct 2021	30 Dec 2021	0.71 Cash
14 Sep 2021	26 Jul 2021	29 Sep 2021	0.71 Cash
14 Jun 2021	27 Apr 2021	29 Jun 2021	0.71 Cash
12 Mar 2021	02 Feb 2021	30 Mar 2021	0.71 Cash
14 Dec 2020	26 Oct 2020	30 Dec 2020	0.68 Cash
14 Sep 2020	29 Jul 2020	29 Sep 2020	0.68 Cash
11 Jun 2020	29 Apr 2020	29 Jun 2020	0.68 Cash
12 Mar 2020	03 Feb 2020	30 Mar 2020	0.68 Cash
12 Dec 2019	23 Oct 2019	30 Dec 2019	0.63 Cash
12 Sep 2019	29 Jul 2019	27 Sep 2019	0.63 Cash
13 Jun 2019	01 May 2019	27 Jun 2019	0.63 Cash
14 Mar 2019	01 Feb 2019	28 Mar 2019	0.63 Cash
13 Dec 2018	24 Oct 2018	28 Dec 2018	0.57 Cash
13 Sep 2018	24 Jul 2018	27 Sep 2018	0.57 Cash
14 Jun 2018	30 Apr 2018	28 Jun 2018	0.57 Cash
15 Mar 2018	05 Feb 2018	29 Mar 2018	0.57 Cash
14 Dec 2017	25 Oct 2017	28 Dec 2017	0.52 Cash
14 Sep 2017	25 Jul 2017	28 Sep 2017	0.52 Cash
14 Jun 2017	01 May 2017	29 Jun 2017	0.52 Cash
14 Mar 2017	06 Feb 2017	30 Mar 2017	0.52 Cash
13 Dec 2016	31 Oct 2016	29 Dec 2016	0.47 Cash
14 Sep 2016	22 Jul 2016	29 Sep 2016	0.47 Cash
14 Jun 2016	27 Apr 2016	29 Jun 2016	0.47 Cash
14 Mar 2016	02 Feb 2016	30 Mar 2016	0.43 Cash
14 Dec 2015	26 Oct 2015	30 Dec 2015	0.43 Cash
14 Sep 2015	23 Jul 2015	29 Sep 2015	0.43 Cash
12 Jun 2015	24 Apr 2015	29 Jun 2015	0.43 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2024	3.08	4	3.40
2023	3.00	4	3.70
2022	2.92	4	3.40
2021	2.84	4	3.91
2020	2.72	4	4.67
2019	2.52	4	3.88
2018	2.28	4	3.65
2017	2.08	4	2.90
2016	1.84	4	2.57
2015	1.29	3	1.28
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2024	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	0.44%
Operating Margin (TTM)	41.96%
Diluted EPS (TTM)	0.090
Quarterly Revenue Growth (YOY)	7.00%
Quarterly Earnings Growth (YOY)	-42.50%

Total Debt/Equity (MRQ)	126.42%
Current Ratio (MRQ)	1.26
Operating Cash Flow (TTM)	10.02 B
Levered Free Cash Flow (TTM)	9.08 B

Return on Assets (TTM)	11.96%
Return on Equity (TTM)	0.56%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)